{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:46:17Z","timestamp":1769067977067,"version":"3.49.0"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hangzhou Health Science and Technology Planning Project","award":["OO20190083"],"award-info":[{"award-number":["OO20190083"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,12,21]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The use of the vancomycin minimum inhibitory concentration (MIC) as a prognostic predictor in patients with methicillin-susceptible\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MSSA) has been debated in the last decade. We performed a systematic review and meta-analysis to investigate whether an elevated vancomycin MIC is associated with a worse prognosis for patients with MSSA bacteraemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed, Embase and the Cochrane Library were searched from inception to December 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Randomised controlled trials or observational studies were considered eligible if they provided clinical outcomes of patients with MSSA bacteraemia, stratified by vancomycin MIC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis<\/jats:title>\n                    <jats:p>Primary outcome was mortality. Secondary outcomes included septic thrombophlebitis, persistent bacteraemia and complicated bacteraemia. Pooled ORs and 95% CIs were calculated. Subgroup analyses included the susceptibility testing method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifteen observational studies were included. Bacteraemia due to MSSA isolates with high vancomycin MICs was associated with higher mortality than isolates with low MICs (OR 1.44; 95%\u2009CI 1.12 to 1.84; I\n                      <jats:sup>2<\/jats:sup>\n                      =40.3%). Additionally, significantly greater septic thrombophlebitis (OR 3.16; 95%\u2009CI 1.11 to 9.00; I\n                      <jats:sup>2<\/jats:sup>\n                      =58.6%) and a trend towards more persistent bacteraemia (OR 1.79; 95%\u2009CI 0.97 to 3.31; I\n                      <jats:sup>2<\/jats:sup>\n                      =0%) were observed in patients with high vancomycin MICs than in patients with low MICs. Differences in complicated bacteraemia were not significant. Similar findings were obtained in subgroup analyses using Etest. However, significant differences in outcomes were not observed between the high and low vancomycin MICs detected using broth microdilution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The available data suggest an association between elevated vancomycin MICs detected using Etest and adverse clinical outcomes for patients with MSSA bacteraemia. Future studies should validate these findings and explore the potential mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42018090547.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040675","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T11:45:28Z","timestamp":1610711128000},"page":"e040675","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of the vancomycin minimum inhibitory concentration on clinical outcomes in patients with methicillin-susceptible\n                    <i>Staphylococcus aureus<\/i>\n                    bacteraemia: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"11","author":[{"given":"Changcheng","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renjie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shaoxing Women and Children's Hospital, Shaoxing, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Xu","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Center, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Teng","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-802X","authenticated-orcid":false,"given":"Nengming","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"2025121510340892000_11.1.e040675.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03903.x"},{"key":"2025121510340892000_11.1.e040675.2","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"2025121510340892000_11.1.e040675.3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ308"},{"key":"2025121510340892000_11.1.e040675.4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-279"},{"key":"2025121510340892000_11.1.e040675.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-07"},{"key":"2025121510340892000_11.1.e040675.6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"2025121510340892000_11.1.e040675.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025121510340892000_11.1.e040675.8","doi-asserted-by":"publisher","DOI":"10.3201\/eid1706.101037"},{"key":"2025121510340892000_11.1.e040675.9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir270"},{"key":"2025121510340892000_11.1.e040675.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6364"},{"key":"2025121510340892000_11.1.e040675.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"2025121510340892000_11.1.e040675.12","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121510340892000_11.1.e040675.13","first-page":"353","article-title":"Staphylococcus aureus bacteremia in a secondary level Spanish Hospital: clinical implications of high vancomycin MIC","volume":"31","author":"Abelenda Alonso","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"2025121510340892000_11.1.e040675.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00658-16"},{"key":"2025121510340892000_11.1.e040675.15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijantimicag.2017.12.028","article-title":"No effect of vancomycin MIC\u2009\u2265\u20091.5\u2009mg\/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia","volume":"51","author":"Bouiller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025121510340892000_11.1.e040675.16","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2014.931596"},{"key":"2025121510340892000_11.1.e040675.17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu183"},{"key":"2025121510340892000_11.1.e040675.18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10096-019-03500-7","article-title":"Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus","volume":"38","author":"Falc\u00f3n","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025121510340892000_11.1.e040675.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.002"},{"key":"2025121510340892000_11.1.e040675.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00757-12"},{"key":"2025121510340892000_11.1.e040675.21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv133"},{"key":"2025121510340892000_11.1.e040675.22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3201\/eid2206.151709","article-title":"High MICs for vancomycin and daptomycin and complicated catheter-related bloodstream infections with methicillin-sensitive Staphylococcus aureus","volume":"22","author":"San-Juan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2025121510340892000_11.1.e040675.23","doi-asserted-by":"crossref","first-page":"e01845","DOI":"10.1128\/AAC.01845-16","article-title":"Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections","volume":"61","author":"Song","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121510340892000_11.1.e040675.24","doi-asserted-by":"crossref","first-page":"e00316","DOI":"10.1128\/AAC.00316-17","article-title":"Reduced vancomycin susceptibility of methicillin-susceptible Staphylococcus aureus has no significant impact on mortality but results in an increase in complicated infection","volume":"61","author":"Sullivan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121510340892000_11.1.e040675.25","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt337"},{"key":"2025121510340892000_11.1.e040675.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.01.017"},{"key":"2025121510340892000_11.1.e040675.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.08.005"},{"key":"2025121510340892000_11.1.e040675.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir935"},{"key":"2025121510340892000_11.1.e040675.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.07.023"},{"key":"2025121510340892000_11.1.e040675.30","doi-asserted-by":"publisher","DOI":"10.1086\/605636"},{"key":"2025121510340892000_11.1.e040675.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.014"},{"key":"2025121510340892000_11.1.e040675.32","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3201\/eid1711.110799","article-title":"Reduced susceptibility to vancomycin in Staphylococcus aureus","volume":"17","author":"Mimica","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2025121510340892000_11.1.e040675.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsre.2003.09.003"},{"key":"2025121510340892000_11.1.e040675.34","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01320-14"},{"key":"2025121510340892000_11.1.e040675.35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00918-10"},{"key":"2025121510340892000_11.1.e040675.36","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-012-0348-0"},{"key":"2025121510340892000_11.1.e040675.37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010790"},{"key":"2025121510340892000_11.1.e040675.38","doi-asserted-by":"crossref","first-page":"e01579","DOI":"10.1128\/AAC.01579-19","article-title":"Relationship between vancomycin MIC and virulence gene expression in clonal complexes of methicillin-susceptible Staphylococcus aureus strains isolated from left-sided endocarditis","volume":"64","author":"Peric\u00e0s","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121510340892000_11.1.e040675.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ583"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:34:17Z","timestamp":1765823657000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,15]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/bmjopen-2020-040675"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040675","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}